Ilia Kassirov

Dr. Ilia Kassirov

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
LSLiubov Shkodenko
Liubov Shkodenko
IKIlia Kassirov
Ilia Kassirov
EKElena I. Koshel
Elena I. Koshel
At present, there is an urgent need in medicine and industry to develop new approaches to eliminate bacterial biofilms. Considering the low efficiency of classical approaches to biofilm eradication and the growing problem of antibiotic resistance, the introduction of nanomaterials may be a promising solution. Outstanding antimicrobial properties have been demonstrated by nanoparticles (NPs) of metal oxides and their nanocomposites. The review presents a comparative analysis of antibiofilm properties of various metal oxide NPs (primarily, CuO, Fe3O4, TiO2, ZnO, MgO, and Al2O3 NPs) and nanocomposites, as well as mechanisms of their effect on plankton bacteria cells and biofilms. The potential mutagenicity of metal oxide NPs and safety problems of their wide application are also discussed.

23 September 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
EGEkaterina A. Goncharova
Ekaterina A. Goncharova
VDVladimir G. Dedkov
Vladimir G. Dedkov
Anna Sergeevna DolgovaAnna Sergeevna Dolgova
Anna Sergeevna Dolgova
IKIlia Kassirov
Ilia Kassirov
MSMarina V. Safonova
Marina V. Safonova
ATAreg A. Totolian
Areg A. Totolian
Coronavirus disease 2019 (COVID‐19) has become pandemic since March 11, 2020. Thus, development and integration in clinics of fast and sensitive diagnostic tools are essential. The aim of the study is a development and evaluation of a one‐step quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) assay (COVID‐19 Amp) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection with an armored positive control and internal controls constructed from synthetic MS2‐phage‐based RNA particles. The COVID‐19 Amp assay limit of detection was 103 copies/ml, the analytical specificity was 100%. A total of 109 biological samples were examined using COVID‐19 Amp and World Health Organization (WHO)‐based assay. Discordance in nine samples was observed (negative by the WHO‐based assay) and discordant samples were retested as positive according to the results obtained from the Vector‐PCRrv‐2019‐nCoV‐RG assay. The developed COVID‐19 Amp assay has high sensitivity and specificity, includes virus particles‐based controls, provides the direct definition of the SARS‐CoV‐2 RdRp gene partial sequence, and is suitable for any hospital and laboratory equipped for RT‐qPCR.

1 January 2020
Verified
Conference Paper
Closed access
SISaint-Petersburg Pasteur Institute
Saint-Petersburg Pasteur Institute
IKIlia Kassirov
Ilia Kassirov
EGE.A. Goncharova
E.A. Goncharova
EZElena V. Zueva
Elena V. Zueva
Anna Sergeevna DolgovaAnna Sergeevna Dolgova
Anna Sergeevna Dolgova


5 October 2020
Verified
Conference Paper
Closed access
EGE.A. Goncharova
E.A. Goncharova
Anna Sergeevna DolgovaAnna Sergeevna Dolgova
Anna Sergeevna Dolgova
IKIlia Kassirov
Ilia Kassirov
ALA.P. Luch
A.P. Luch
VDVladimir George Dedkov
Vladimir George Dedkov